The efficacy of brexpiprazole across a spectrum of schizophrenia symptoms was evaluated in patients with acute schizophrenia in 2 short-term 6-week studies and in a long-term 52-week maintenance study using the 5 previously validated PANSS-derived Marder factors.[1–3] The analysis was performed on the pooled data from two 6-week, double-blind, placebo-controlled studies of patients with schizophrenia who were randomly assigned to fixed once-daily doses of brexpiprazole 2 mg (n = 359), 4 mg (n = 359), or placebo (n = 358; NCT01396421 and NCT01393613), and in one 52-week, double-blind, placebo-controlled study with patients randomized to bexpiprazole (1–4 mg; n = 97) and placebo, n = 105 [NCT01668797]). The maintenance study included a stabilization phase in which patients needed to be stable on brexpiprazole for at least 12 weeks before randomization to brexpiprazole or placebo. In the short-term studies, brexpiprazole 4 mg and 2 mg were each superior to placebo in change from baseline in PANSS Total score at Week 6 (least square mean difference [LSMD] versus placebo: −6.69, < .0001 and −5.46, = .0004, respectively). The LSMD versus placebo at Week 6 was also significant (